One of the world’s foremost biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Founded in Boston in 1981, Genzyme has grown from a small start-up to a diversified enterprise with annual revenues exceeding $3 billion and more than 9,500 employees in locations spanning the globe. With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company’s products and services are... focused on rare inherited disorders, kidney disease, orthopaedics, transplant, cancer, and diagnostic testing. Genzyme’s commitment to innovation continues today with a substantial research and development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.
more
| NASDAQ symbol: | GENZ |
| Headquarters: | Cambridge, Massachusetts |
| Annual revenue: | $4,605,040,000 |
| Net income: | $421,080,000 |
| Operating income: | $581,480,000 |
| Market cap: | $20,000,000,000 |
| Employees: | 12,000 |
| Industries: | Biological Product (except Diagnostic) Manufacturing, Biotechnology |